MARKET

LPTX

LPTX

Leap Therapeutic
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.180
-0.050
-4.07%
Opening 13:01 06/29 EDT
OPEN
1.230
PREV CLOSE
1.230
HIGH
1.240
LOW
1.150
VOLUME
402.03K
TURNOVER
229.64K
52 WEEK HIGH
4.170
52 WEEK LOW
0.9200
MARKET CAP
104.22M
P/E (TTM)
-2.1643
1D
5D
1M
3M
1Y
5Y
Cybin (CYBN) Up on FDA Clearance of IND for CYB003 in MDD
Cybin (CYBN) receives a "may proceed letter" and IND application clearance from the FDA for a phase I/IIa study evaluating CYB003 for potential treatment of major depressive disorder. Shares up.
Zacks · 1d ago
Leap Therapeutics to Host Virtual R&D Day on July 12, 2022
Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it will host a virtual R&D Day on July 12, 2022 at 12:00 pm ET. Leap's executive management team will be j...
PR Newswire · 2d ago
Blueprint Medicines' (BPMC) Ayvakit Aids Growth Amid Rivalry
Blueprint Medicines' (BPMC) lead drug, Ayvakit, approved to treat rare cancer and other rare diseases, has seen strong uptake since approval. However, stiff competition remains a concern.
Zacks · 06/17 15:16
Immunovant (IMVT) Set on Lead Candidate Batoclimab's Development
Immunovant (IMVT) remains focused on developing lead pipeline candidate, batoclimab for treating several types of autoimmune diseases. Lack of other pipeline candidate remains a concern.
Zacks · 06/13 16:01
Alnylam (ALNY) Posts Positive Data From IgA Nephropathy Study
Alnylam (ALNY) reports top-line data from a phase II study evaluating its investigational RNAi therapeutic, cemdisiran, for the treatment of immunoglobulin A nephropathy.
Zacks · 06/10 14:51
Immunovant (IMVT) Sees Wider Q4 Loss, to Study Batoclimab in TED
Immunovant's (IMVT) earnings miss estimates in fiscal fourth quarter ended on Mar 31, 2022. The company achieves FDA alignment for phase III study on batoclimab in thyroid eye disease.
Zacks · 06/09 14:48
Apellis (APLS), Sobi Begin Pegcetacoplan Dosing in Kidney Disease
Apellis (APLS) and Sobi dose the first patient in phase III VALIANT study evaluating pegcetacoplan in primary immune-complex membranoproliferative glomerulonephritis and C3 glomerulopathy. Stock up.
Zacks · 06/08 14:14
Praxis (PRAX) Tanks on Negative Data From Depression Study
Praxis (PRAX) posts negative data from the phase II/III Aria study that evaluated PRAX-114 for monotherapy treatment of major depressive disorder. Shares fall.
Zacks · 06/07 15:30
More
No Data
Learn about the latest financial forecast of LPTX. Analyze the recent business situations of Leap Therapeutic through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

20.00%Strong Buy
80.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average LPTX stock price target is 4.600 with a high estimate of 6.00 and a low estimate of 4.000.
High6.00
Average4.600
Low4.000
Current 1.180
EPS
Actual
Estimate
-0.11-0.08-0.06-0.03
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 98
Institutional Holdings: 47.20M
% Owned: 53.45%
Shares Outstanding: 88.32M
TypeInstitutionsShares
Increased
25
4.45M
New
16
3.27M
Decreased
15
4.75M
Sold Out
14
2.62M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.31%
Pharmaceuticals & Medical Research
+0.75%
Key Executives
Chairman/Director
Christopher Mirabelli
President/Chief Executive Officer/Director
Douglas Onsi
Chief Operating Officer
Augustine Lawlor
Vice President
Christine Granfield
Other
Mark O'Mahony
Other
Cynthia Sirard
Lead Director/Independent Director
Thomas Dietz
Independent Director
Monica Bertagnolli
Independent Director
James Cavanaugh
Independent Director
William Li
Independent Director
Joseph Loscalzo
Independent Director
Nissim Mashiach
No Data
No Data
About LPTX
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. The Company’s clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. When DKN-01 binds to DKK1, an anti-tumor effect can be generated. DKK1 is a cell secreted protein that research has found its role in embryonic development. DKN-01 is an affinity, neutralizing monoclonal antibody targeting DKK1. DKN-01 reduces free DKK1 levels and has demonstrated an anti-tumor effect in preclinical models.

Webull offers kinds of Leap Therapeutics Inc stock information, including NASDAQ:LPTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LPTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LPTX stock methods without spending real money on the virtual paper trading platform.